Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2016 August;82(8) > Minerva Anestesiologica 2016 August;82(8):884-94





A Journal on Anesthesiology, Resuscitation, Analgesia and Intensive Care

Official Journal of the Italian Society of Anesthesiology, Analgesia, Resuscitation and Intensive Care
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,036




Minerva Anestesiologica 2016 August;82(8):884-94

language: English

Bleeding management in patients with new oral anticoagulants

Maria VARGAS 1, Annachiara MARRA 1, Antonietta PERRONE 2, Giuseppe SERVILLO 1

1 Unit of Anesthesia and Intensive Care, Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples “Federico II”, Naples, Italy; 2 Unit of Clinical Engineering, Department of Clinical Engineering, University of Naples “Federico II”, Naples, Italy


New oral anticoagulants (NOACs) have been developed in recent years and are increasingly used in clinical practice. Dabigatran is a direct thrombin (factor II) inhibitor while rivaroxaban, apixaban and edoxaban are direct inhibitors of factor Xa. The European Medicines Agency (EMA) currently approves these NOACs for different clinical uses. NOACs do not require routine monitoring of coagulation although an assessment of anticoagulation activity in these patients may be required in different conditions. NOACs show a similar or lower incidence of bleeding compared with conventional therapies in phase III trials. In case of bleeding, non-specific reversal strategies are available while specific reversal agents are the subject of ongoing trials. The role of this review is to summarize the current knowledge on NOCAs focusing on bleeding management in the perioperative period.

top of page

Publication History

Cite this article as

Corresponding author e-mail